Drugs / Florzolotau
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03625128 | Jan → Aug 2018 | Alzheimer disease, corticobasal syndrome, frontotemporal dementia, progressive supranuclear palsy +1 | Chang Gung Memorial Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Florzolotau | “All subjects were injected with approximately 379.03 ± 7.03 MBq of [18F]Florzolotau intravenously, and a whole-body PET/CT scan was performed for each subject.” PMID 38563872 ↗ Apr 2024 |
| Known as | [18F]Florzolotau | “All subjects were injected with approximately 379.03 ± 7.03 MBq of [18F]Florzolotau intravenously, and a whole-body PET/CT scan was performed for each subject.” PMID 38563872 ↗ Apr 2024 |
| Modality | Diagnostic / imaging agent | “novel tau imaging ligand” NCT03625128 ↗ |
| Route | Intravenous | “injected with approximately 379.03 ± 7.03 MBq of [18F]Florzolotau intravenously” PMID 38563872 ↗ Apr 2024 |